Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

DaVita HealthCare (DVA), a major U.S. dialysis service provider, is highlighted as a compelling value investment despite its current Zacks Rank #3 (Hold). The company earns an 'A' Value Style Score, driven by an attractive forward P/E of 13.64, and a 'B' VGM Score. This positive assessment is reinforced by recent upward revisions to its FY2025 earnings estimates and a consistent 3.6% average earnings surprise, positioning DVA as a notable consideration for value-oriented portfolios.

Analysis

DaVita HealthCare (DVA) presents a mixed but compelling profile for value-oriented investors, according to an analysis based on the Zacks rating system. The company holds a neutral Zacks Rank #3 (Hold), which is counterbalanced by a strong 'A' grade for its Value Style Score and a solid 'B' for its overall VGM Score. The 'A' value rating is substantiated by an attractive forward P/E ratio of 13.64. On the earnings front, the outlook contains some nuances; while one analyst has revised fiscal 2025 earnings estimates higher within the last 60 days, the Zacks Consensus Estimate for that period has remained unchanged at $10.76 per share. This suggests the single revision was not significant enough to move the consensus. Supporting a more positive view, DVA has a consistent track record of outperformance, evidenced by an average earnings surprise of 3.6%.

Key Decisions for Investors

• Value-focused investors may find DVA's forward P/E of 13.64 and 'A' Value Score an attractive entry point, especially if they have a long-term horizon.
• Investors should monitor future earnings estimate revisions closely to see if the recent single upward revision for FY2025 is followed by broader analyst upgrades, as the current static consensus could temper upward momentum.
• Given the neutral Zacks #3 (Hold) rank, a prudent approach could be to hold existing positions or accumulate gradually, waiting for more definitive catalysts before establishing a large, bullish position.